Jefferies upgraded Vertex to Buy from Hold following improved fundamentals and a growing pipeline worth $5 billion-7 billion, which includes treatments for chronic pain and APOL1 kidney disease.

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall. Vertex will continue testing ...

Chair of Vertex’s TDT Program Steering Committee, and Presenting Author of the CASGEVY clinical data at ASH. “With median follow-up around three years there is strong evidence for the ...

Taking place at the Intuit Dome in Los Angeles, California, UFC 311 will be headlined by a lightweight title bout between Islam Makhachev and #1-ranked lightweight contender Arman Tsarukyan in a ...